Quick Facts: Hastina

Condition
Management of heavy menstrual bleeding (menorrhagia) in premenopausal women
Short-term use to reduce or prevent bleeding in patients with hemophilia
Treatment for hereditary angioedema

---

Hastina (Tranexamic Acid) is a medication utilized in the therapeutic management of specific bleeding conditions. Its primary purpose is to support the body's natural ability to stabilize clots, thereby reducing or preventing episodes of excessive blood loss.

For premenopausal women, Hastina is indicated for the management of cyclic heavy menstrual bleeding (menorrhagia), helping to limit the amount of blood loss during the menstrual cycle. This use may contribute to an improved quality of life for those affected by this condition.

Additionally, Hastina is utilized for short-term use in patients diagnosed with hemophilia to help prevent or reduce bleeding, particularly following dental procedures like tooth extractions. It may also be prescribed as a treatment option for the long-term management of hereditary angioedema, a condition characterized by swelling episodes. The drug is associated with therapeutic benefits across these different domains.

Treatment decisions, including whether Hastina is an appropriate option, should always be determined by a healthcare provider after a complete clinical evaluation.

Official Eligibility and Contraindication Profile

Hastina (Tranexamic Acid) is an antifibrinolytic medicine whose use is strictly governed by regulatory documentation, primarily based on an individual's history of blood clotting and kidney function.

Populations for Whom Use is Contraindicated

The medicine must not be used by any individual with:

• Active thromboembolic disease or a history of thrombosis or thromboembolism (e.g., deep vein thrombosis, pulmonary embolism, or retinal vein/artery occlusion).
• An intrinsic risk of thrombosis, such as hypercoagulopathy or thrombogenic valvular or cardiac rhythm disease.
• Concomitant use of combined hormonal contraception (birth control pills, patch, or ring).
• Known hypersensitivity (allergy) to tranexamic acid.
• A history of convulsions or seizures.

Restricted and Conditional Use

Eligibility Group	Regulatory Requirement
Renal Impairment	Conditional use is required; the dosage must be reduced due to the risk of medicine accumulation in the body.
Age Groups	The oral formulation for heavy menstrual bleeding is not intended for use in postmenopausal women. Safety and efficacy are not established in children under 12 years of age for this specific use.
Pregnancy/Lactation	Caution should be exercised. Use is generally reserved for when the potential benefits outweigh the potential risk, as the medicine is excreted into human milk and passes the placenta.

Interactions with other medicines and products

Hastina (a combined hormonal contraceptive) is subject to significant drug-drug interactions that can reduce its therapeutic effectiveness, leading to potential loss of contraceptive protection, or increase the risk of adverse events.

Pharmacokinetic Interaction Mechanisms

Most clinically relevant interactions are mediated by the Cytochrome P450 (CYP) enzyme system, particularly CYP3A4. The synthetic estrogen and progestin components are metabolized by this system.

• Enzyme Inducers: Concomitant use with medicines that induce CYP enzymes (i.e., CYP3A4 inducers) accelerates the metabolism and clearance of the contraceptive steroids, resulting in a reduction of hormone exposure. This significantly compromises contraceptive efficacy. A reduction in estrogen exposure may also lead to changes in the bleeding profile (breakthrough bleeding).
• Enzyme Inhibitors: Medicines that inhibit CYP enzymes can increase plasma concentrations of the contraceptive hormones. For the estrogen component (Ethinyl Estradiol), this elevation can theoretically increase the risk of serious vascular complications, such as thromboembolism.

Interacting Medicines and Products

Specific classes of medicines known to interact via CYP induction include:

• Anticonvulsants: Certain drugs used to treat epilepsy (e.g., phenytoin, carbamazepine, phenobarbital).
• Anti-infectives: Certain medications for tuberculosis (e.g., rifampicin) and some antiretroviral drugs used in HIV treatment.
• Herbal Products: St. John’s Wort (Hypericum perforatum) is a known enzyme inducer that can decrease contraceptive hormone levels, and its concomitant use is generally not recommended with this product class.

Interaction-Related Restrictions and Conditions

Regulatory warnings advise that women taking strong or moderate CYP inducers should use an alternative, non-hormonal, or non-enzyme-affected method of contraception during co-administration and for an extended period (typically 28 days) after discontinuing the interacting medicine. Additionally, combined oral contraceptives containing drospirenone are contraindicated in patients with conditions that predispose to hyperkalemia or while using other potassium-sparing drugs, due to a distinct pharmacodynamic risk of elevated serum potassium.

Dual Intervention in the Ras/MAPK Signaling Cascade

This domain covers Hastina's action on its primary biological targets—the Raf kinases (A-Raf and B-Raf) and the KRAS G-protein. Hastina is a dual inhibitor that acts by blocking the signal transduction pathway at two distinct molecular points, thereby reducing signal transmission through the Raf/MEK/ERK cascade and modulating subsequent molecular events.

Modulating Cellular Proliferation and Survival

This addresses the core mechanistic cascade and resulting physiological effects. By suppressing activity in the Ras/MAPK pathway, Hastina alters the ratio of proliferation-to-apoptosis signals in internal cellular programming. This action modifies early molecular steps that regulate cell growth and survival, which leads to cell cycle arrest and increases the probability of programmed cell death (apoptosis) in specific cell populations.

Targeted Suppression of Dysregulated Signaling

This domain explains the importance of the mechanism in physiological context. Hastina engages mechanisms that are relevant in biological systems where specific signaling pathways, like Ras/MAPK, are overactive or dysregulated. This establishes a suppressed state of signaling within the targeted pathways and decreases the influence of heightened growth mediator activity.

How to Use Hastina: Official Administration Guidelines

Hastina (Tranexamic Acid) must be used strictly according to the official instructions. The medicine is available for systemic administration via two approved routes: oral tablets and intravenous (IV) injection.

---

Official Dosing and Scheduling

Approved Use	Dosage Regimen	Frequency & Duration	Key Constraint
Heavy Menstrual Bleeding	1300 mg (two 650 mg tablets)	Three times daily (TID)	Maximum of 5 days during monthly menstruation.
Hemophilia (Dental)	10 mg/kg actual body weight (IV)	3 to 4 times daily for 2 to 8 days	Infusion must not exceed 1 mL/minute.

Administration Requirements

Oral Tablets:

• The tablets may be administered with or without food.
• Tablets must be swallowed whole; they should not be chewed or broken apart.

Intravenous Injection:

• The injection is for IV use only; administration via other routes is contraindicated.
• The solution must be infused slowly. Rapid intravenous injection may cause hypotension.

Population-Specific Adjustment

Renal Impairment: Dosage adjustment (reduction) is mandatory for patients with impaired renal function due to the risk of drug accumulation. The dose is reduced based on serum creatinine concentration. No dosage adjustment is generally necessary for patients with hepatic impairment.

Research Evidence / Overview of Studies for Hastina (Tranexamic Acid)

---

Evidence for use in Cyclic Heavy Menstrual Bleeding (Menorrhagia)

The core research for Hastina's use in heavy menstrual bleeding, a condition characterized by conditions presenting with cycles of stability and flare-ups, has utilized Randomized Controlled Trial (RCT) designs and systematic reviews. These trials were applied in studies examining patient-reported experiences and relevant in evidence describing how symptoms are measured. The research examined outcomes related to physiological strain or stress, particularly the quantification of menstrual blood loss (MBL), alongside patient-reported outcomes. Studies reported measurements of MBL that were lower in the groups receiving the medicine compared to placebo groups across several treatment cycles. The body of evidence includes multiple studies and contributes to the broader evidence landscape.

However, the results apply only to the populations studied. Most clinical trials was observed in populations that specifically excluded women who were also using other hormonal treatments. Long-term effects are not fully established beyond the few menstrual cycles typically monitored in the main trials.

---

Evidence for use in Short-Term Bleeding Prevention (Hemophilia)

Research on Hastina for use in controlling bleeding, particularly after procedures like dental extractions in patients with hemophilia, was studied for its effect on outcomes describing episodic or acute changes. The evidence base for this specific scenario is limited and consists primarily of a small number of older Randomized and Quasi-Randomized Controlled Trials. Trial reports described patterns where the number of immediate bleeding events was observed to be lower, and the monitored use of clotting factor replacement was also observed to be lower, when compared to control groups. The follow-up durations were limited, typically covering only the few days immediately following the procedure.

---

What is Still Uncertain About Hastina's Research

The overall research landscape evidence highlights what is known — and what is still uncertain. Key uncertainties revolve around the follow-up durations were limited in many studies, meaning that the full effects and consistency of the medicine over many years are not well characterized. Furthermore, evidence quality varies across studies, particularly for the less common indications like Hereditary Angioedema, where comparative evidence is lacking against modern treatments. The lack of data on certain patient subgroups means that the research provides context but not individual predictions for these specific groups.

Key Studies & References

1. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions (Cochrane Review/Evidence for Hemophilia)
2. Clinical Practice Guidelines: Hereditary angioedema (C1-esterase inhibitor deficiency) (Guideline source for HAE evidence quality and limitations)

Common questions about Hastina (FAQ)

Q: What is the main condition Hastina is approved to treat?

A: Hastina is the name used for two different types of treatments. In some contexts, it refers to a Combined Oral Contraceptive (COC) for the prevention of pregnancy. In another, it refers to an antifibrinolytic medicine (Tranexamic Acid) approved for the short-term treatment of heavy menstrual bleeding and bleeding prevention in certain procedures. Official labeling covers both these primary therapeutic areas.

Q: Can Hastina cause weight changes?

A: Regulatory documents for the combined oral contraceptive formulation list weight gain as a potential side effect. This information is included in the safety profile provided in official product documents.

Q: How quickly can I expect Hastina to start having an effect?

A: For the combined oral contraceptive formulation, pharmacokinetic studies indicate that the active components typically reach a steady concentration in the bloodstream after about 7 to 8 days of daily dosing. The onset of noticeable effects is not uniformly defined in product labeling.

Q: Does Hastina affect blood pressure?

A: Official information provides two specific points regarding blood pressure. The antifibrinolytic formulation for injection carries a warning that rapid intravenous administration may cause a sudden drop in blood pressure (hypotension). Additionally, the combined oral contraceptive formulation is generally contraindicated in patients who have uncontrolled high blood pressure.

Q: What happens if I miss a dose of Hastina?

A: Regulatory guidance for the combined oral contraceptive formulation provides specific instructions for managing missed tablets, which vary based on the number of pills missed and where you are in the treatment cycle. Regulatory documents for the antifibrinolytic formulation do not provide specific guidance on managing a missed dose for short-term use.

Q: Do I need to change my diet while using Hastina?

A: Official prescribing information indicates that the oral tablets can be taken with or without food. Specific diet changes or restrictions are not listed in the official product labeling.

Q: Are there any major food or drink items to avoid while taking Hastina?

A: The labeling does not list specific foods or drinks to avoid. However, substances that are strong inhibitors of the CYP3A4 enzyme could potentially increase the concentration of the contraceptive hormones. This interaction mechanism is described in official product information.

Q: Does Hastina interact with common over-the-counter pain relievers?

A: The combined oral contraceptive formulation contains a component, drospirenone, that may influence potassium levels. Official documents advise caution regarding its use with NSAIDs (a type of common pain reliever) in high-risk patients due to the potential for elevated serum potassium.

Q: Is Hastina known to cause problems with sleep?

A: Difficulty in sleeping and a tired feeling are listed as potential side effects of the combined oral contraceptive formulation. This information is included in the official documentation of the medicine’s adverse reactions.

Q: How long does the effect of one dose of Hastina typically last?

A: Pharmacokinetic studies provide data on how long the drug components remain in the body. For the combined oral contraceptive, the terminal half-life for one of the main components is approximately 30 hours. The antifibrinolytic formulation has a different and shorter half-life than the contraceptive components, as described in pharmacokinetic data.

Q: Does Hastina have a warning about driving or operating machinery?

A: Due to the potential for dizziness and visual disturbances listed as side effects for the antifibrinolytic formulation, caution regarding driving or operating machinery is noted in the product information.

Q: Does the time of day matter when taking Hastina?

A: For the combined oral contraceptive formulation, regulatory guidance specifies that the tablets must be taken by mouth at the same time every day. Taking the tablets at the same time every day is specified in the regulatory guidance to achieve maximum contraceptive effectiveness.

Q: How is Hastina usually stopped when treatment is complete?

A: The method for stopping treatment depends on the formulation. The antifibrinolytic oral treatment for heavy menstrual bleeding is intended for short-term use, taken for a maximum of five days. The combined oral contraceptive treatment is stopped by completing the active pills in the pack, and specific instructions are provided for discontinuing use before major surgeries.

Q: Can using Hastina affect laboratory test results?

A: Yes, regulatory documents note that the combined oral contraceptive can affect laboratory test results. Specifically, it increases the serum concentration of certain binding globulins, which may influence the results of associated blood tests. Additionally, monitoring of serum potassium is advised in certain high-risk patients due to one of the components.

Q: What happens if Hastina is taken with a strong grapefruit product?

A: Official labeling advises caution with strong inhibitors of the CYP3A4 enzyme. Substances that are strong CYP3A4 inhibitors could potentially increase the concentration of the contraceptive hormones, as described in official documentation.

Hastina (Tranexamic Acid) must be stored and disposed of according to strict official guidelines to ensure product stability and public safety.

Official Storage Conditions

Requirement	Details
Temperature	Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with excursions permitted between 15 C and 30 C.
Protection	Keep the product away from excessive heat, moisture, and direct light. Keep the container tightly closed.
Child Safety	The medicine must be stored out of the sight and reach of children (keep locked up).

Disposal Instructions

Official disposal protocols recommend utilizing drug take-back programs as the best option for discarding unused or expired Hastina. If no take-back program is available, the medicine should be removed from its container, mixed with an undesirable substance (such as used coffee grounds or dirt), sealed in a bag or container, and placed into the household trash. The empty packaging must have all personal information scratched out before disposal. The medicine should not be flushed down a toilet or poured down a drain unless explicitly instructed by the official labeling.